Biotin status of epileptics

Area of Science:

• Biochemistry
• Neurology
• Clinical Medicine

Background:

• Epilepsy treatment often involves long-term anticonvulsant therapy.
• Potential biochemical alterations associated with anticonvulsant use require investigation.

Purpose of the Study:

• To investigate plasma biotin levels in epileptic patients undergoing anticonvulsant treatment.
• To explore the relationship between specific anticonvulsants, epilepsy type, and biotin status.
• To assess potential biochemical consequences of reduced biotin levels in epilepsy.

Main Methods:

• Microbiological assay of plasma biotin levels in 404 epileptic patients and 112 controls.
• Analysis of biotin levels in relation to epilepsy type (partial vs. generalized), anticonvulsant monotherapy (valproate, primidone, carbamazepine, phenytoin, phenobarbital), and dosage.
• Measurement of urinary organic acid excretion and plasma lactate concentrations in subsets of patients.

Main Results:

• Epileptic patients exhibited significantly lower plasma biotin levels compared to controls (p < 0.0005).
• Lower biotin levels were observed in partial epilepsy and with higher anticonvulsant doses.
• Valproate monotherapy was associated with higher biotin levels than other monotherapies; certain anticonvulsants increased organic acid excretion, indicative of biotin-dependent carboxylase deficiency.
• Elevated plasma lactate concentrations were found in patients on long-term treatment.

Conclusions:

• Anticonvulsant intake is strongly suggested to lower biotin levels in epilepsy patients.
• Reduced biotin levels and associated biochemical effects, such as increased organic acid and lactate levels, may occur during anticonvulsant therapy.
• The potential role of biotin deficiency in the mechanism of action of anticonvulsants warrants further discussion and research.